Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Guidance On Combo HIV Products Will Allow Reviews In Six Weeks

Executive Summary

FDA is setting a goal of reviewing fixed-dose combinations of HIV drugs in six weeks as part of the Bush Administration's $15 bil. Emergency Plan for AIDS Relief

You may also be interested in...



Most Expedited Reviews For Generic HIV Drugs Are For Single Agents – FDA

FDA is expanding its program to expedite the review of fixed-dose combination and co-packaged HIV drugs to include single-ingredient copies of certain antiretroviral drugs, according to a recently released final guidance

Most Expedited Reviews For Generic HIV Drugs Are For Single Agents – FDA

FDA is expanding its program to expedite the review of fixed-dose combination and co-packaged HIV drugs to include single-ingredient copies of certain antiretroviral drugs, according to a recently released final guidance

Co-Packaged HIV Drug User Fees Likely To Be Waived By AIDS Relief Plan

Most fixed-dose combination and co-packaged versions of previously approved antiretroviral HIV therapies are unlikely to require user fees under the President's $15 bil. Emergency Plan for AIDS Relief, according to a 1draft guidance released April 15

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS044020

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel